{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T12:38:51Z","timestamp":1769949531774,"version":"3.49.0"},"reference-count":49,"publisher":"e-Century Publishing Corporation","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/bzed8420","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T03:47:41Z","timestamp":1740714461000},"page":"1290-1301","source":"Crossref","is-referenced-by-count":1,"title":["Effect of proton pump inhibitor (lansoprazole) on adverse drug reactions and rational drug use in elderly patients with chronic heart failure"],"prefix":"10.62347","volume":"17","author":[{"given":"Lei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/MCG.0000000000001420","article-title":"Proton pump inhibitor use, hypomagnesemia and risk of cardiovascular diseases: the atherosclerosis risk in communities (ARIC) study","volume":"55","author":"Rooney","year":"2021","unstructured":"Rooney MR, Bell EJ, Alonso A, Pankow JS, Demmer RT, Rudser KD, Chen LY and Lutsey PL. Proton pump inhibitor use, hypomagnesemia and risk of cardiovascular diseases: the atherosclerosis risk in communities (ARIC) study. J Clin Gastroenterol 2021; 55: 677-683.","journal-title":"J Clin Gastroenterol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/14740338.2020.1700228","article-title":"Adverse cardiovascular and blood pressure effects of drug-induced hypomagnesemia","volume":"19","author":"Chrysant","year":"2020","unstructured":"Chrysant SG and Chrysant GS. Adverse cardiovascular and blood pressure effects of drug-induced hypomagnesemia. Expert Opin Drug Saf 2020; 19: 59-67.","journal-title":"Expert Opin Drug Saf"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/qjmed\/hcz166","article-title":"Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis","volume":"112","author":"Grant","year":"2019","unstructured":"Grant CH, Gillis KA, Lees JS, Traynor JP, Mark PB and Stevens KI. Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis. QJM 2019; 112: 835-840.","journal-title":"QJM"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/ijms21010323","article-title":"The use of proton pump inhibitors may increase symptoms of muscle function loss in patients with chronic illnesses","volume":"21","author":"Vinke","year":"2020","unstructured":"Vinke P, Wesselink E, van Orten-Luiten W and van Norren K. The use of proton pump inhibitors may increase symptoms of muscle function loss in patients with chronic illnesses. Int J Mol Sci 2020; 21: 323.","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.mayocp.2021.02.025","article-title":"Association of proton pump inhibitors with higher risk of cardiovascular disease and heart failure","volume":"96","author":"Bell","year":"2021","unstructured":"Bell EJ, Bielinski SJ, St Sauver JL, Chen LY, Rooney MR, Larson NB, Takahashi PY and Folsom AR. Association of proton pump inhibitors with higher risk of cardiovascular disease and heart failure. Mayo Clin Proc 2021; 96: 2540-2549.","journal-title":"Mayo Clin Proc"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.5009\/gnl20036","article-title":"Proton pump inhibitor-related gastric mucosal changes","volume":"15","author":"Kim","year":"2021","unstructured":"Kim GH. Proton pump inhibitor-related gastric mucosal changes. Gut Liver 2021; 15: 646-652.","journal-title":"Gut Liver"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR and Yancy CW. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 2022; 145: e876-e894.","DOI":"10.1161\/CIR.0000000000001063"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41397-020-00189-2","article-title":"The need of a multicomponent guiding approach to personalize clopidogrel treatment","volume":"21","author":"Valeria","year":"2021","unstructured":"Valeria C, Carmine S, Valentina M, Teresa I, Maria C, Martina T, Giancarlo A, Giovanna N, Graziamaria C and Amelia F. The need of a multicomponent guiding approach to personalize clopidogrel treatment. Pharmacogenomics J 2021; 21: 116-127.","journal-title":"Pharmacogenomics J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-020-0151-7","article-title":"Acute heart failure","volume":"6","author":"Arrigo","year":"2020","unstructured":"Arrigo M, Jessup M, Mullens W, Reza N, Shah AM, Sliwa K and Mebazaa A. Acute heart failure. Nat Rev Dis Primers 2020; 6: 16.","journal-title":"Nat Rev Dis Primers"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective","volume":"124","author":"MA","year":"2019","unstructured":"Pfeffer MA, Shah AM and Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res 2019; 124: 1598-1617.","journal-title":"Circ Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40266-019-00704-6","article-title":"Proton pump inhibitors and infection-related hospitalizations among residents of long-term care facilities: a case-control study","volume":"36","author":"Wang","year":"2019","unstructured":"Wang KN, Bell JS, Tan ECK, Gilmartin-Thomas JFM, Dooley MJ and Ilomaki J. Proton pump inhibitors and infection-related hospitalizations among residents of long-term care facilities: a case-control study. Drugs Aging 2019; 36: 1027-1034.","journal-title":"Drugs Aging"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5455\/medarh.2022.76.17-22","article-title":"Clinical Implications of functional mitral regurgitation severity in patients with heart failure with reduced ejection fraction (HFrEF)","volume":"76","author":"Naser","year":"2022","unstructured":"Naser N. Clinical Implications of functional mitral regurgitation severity in patients with heart failure with reduced ejection fraction (HFrEF). Med Arch 2022; 76: 17-22.","journal-title":"Med Arch"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F and Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726.","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ccl.2021.12.011","article-title":"Hypertension and heart failure: prevention, targets, and treatment","volume":"40","author":"Di Palo","year":"2022","unstructured":"Di Palo KE and Barone NJ. Hypertension and heart failure: prevention, targets, and treatment. Cardiol Clin 2022; 40: 237-244.","journal-title":"Cardiol Clin"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10557-020-06987-x","article-title":"Artificial intelligence uncovered clinical factors for cardiovascular events in myocardial infarction patients with glucose intolerance","volume":"34","author":"Shindo","year":"2020","unstructured":"Shindo K, Fukuda H, Hitsumoto T, Miyashita Y, Kim J, Ito S, Washio T and Kitakaze M. Artificial intelligence uncovered clinical factors for cardiovascular events in myocardial infarction patients with glucose intolerance. Cardiovasc Drugs Ther 2020; 34: 535-545.","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2169\/internalmedicine.2608-18","article-title":"Proton-pump inhibitor-induced severe hypomagnesemia and hypocalcemia are clinically masked by thiazide diuretic","volume":"58","author":"Uehara","year":"2019","unstructured":"Uehara A, Kita Y, Sumi H and Shibagaki Y. Proton-pump inhibitor-induced severe hypomagnesemia and hypocalcemia are clinically masked by thiazide diuretic. Intern Med 2019; 58: 2201-2205.","journal-title":"Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccep.2018.11.001","article-title":"The many faces of heart failure","volume":"11","author":"Snipelisky","year":"2019","unstructured":"Snipelisky D, Chaudhry SP and Stewart GC. The many faces of heart failure. Card Electrophysiol Clin 2019; 11: 11-20.","journal-title":"Card Electrophysiol Clin"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Shakhmatova OO, Komarov AL, Korobkova VV, Yarovaya EB, Andreevskaya MV, Shuleshova AG and Panchenko EP. Upper gastrointestinal bleeding in patients with stable coronary artery disease (registry of antithrombotic therapy “REGATcapital TE, CyrillicA” results). Ter Arkh 2020; 92: 30-38.","DOI":"10.26442\/00403660.2020.09.000699"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/ehf2.12555","article-title":"Highlights in heart failure","volume":"6","author":"Tomasoni","year":"2019","unstructured":"Tomasoni D, Adamo M, Lombardi CM and Metra M. Highlights in heart failure. ESC Heart Fail 2019; 6: 1105-1127.","journal-title":"ESC Heart Fail"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1021\/acs.jmedchem.7b00574","article-title":"Modulators of 14-3-3 protein-protein interactions","volume":"61","author":"LM","year":"2018","unstructured":"Stevers LM, Sijbesma E, Botta M, MacKintosh C, Obsil T, Landrieu I, Cau Y, Wilson AJ, Karawajczyk A, Eickhoff J, Davis J, Hann M, O’Mahony G, Doveston RG, Brunsveld L and Ottmann C. Modulators of 14-3-3 protein-protein interactions. J Med Chem 2018; 61: 3755-3778.","journal-title":"J Med Chem"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.therap.2020.06.019","article-title":"Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations","volume":"76","author":"Koyyada","year":"2021","unstructured":"Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie 2021; 76: 13-21.","journal-title":"Therapie"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jamda.2020.09.046","article-title":"The use and misuse of proton pump inhibitors: an opportunity for deprescribing","volume":"22","author":"Dharmarajan","year":"2021","unstructured":"Dharmarajan TS. The use and misuse of proton pump inhibitors: an opportunity for deprescribing. J Am Med Dir Assoc 2021; 22: 15-22.","journal-title":"J Am Med Dir Assoc"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","unstructured":"Savarese G, Stolfo D, Sinagra G and Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol 2022; 19: 100-116.","journal-title":"Nat Rev Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.7861\/clinmed.2021-0039","article-title":"Non-steroidal anti-inflammatory drugs and the gastrointestinal tract","volume":"21","author":"Tai","year":"2021","unstructured":"Tai FWD and McAlindon ME. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. Clin Med (Lond) 2021; 21: 131-134.","journal-title":"Clin Med (Lond)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1136\/heartjnl-2021-319321","article-title":"Aspirin versus P2Y(12) inhibitors with anticoagulation therapy for atrial fibrillation","volume":"107","author":"Fukaya","year":"2021","unstructured":"Fukaya H, Ako J, Yasuda S, Kaikita K, Akao M, Matoba T, Nakamra M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K and Ogawa H. Aspirin versus P2Y(12) inhibitors with anticoagulation therapy for atrial fibrillation. Heart 2021; 107: 1731-1738.","journal-title":"Heart"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Kurlander JE, Barnes GD, Fisher A, Gonzalez JJ, Helminski D, Saini SD, Sengupta N, Yang YX, Scheiman J and Laine L. Association of antisecretory drugs with upper gastrointestinal bleeding in patients using oral anticoagulants: a systematic review and meta-analysis. Am J Med 2022; 135: 1231-1243.e1238.","DOI":"10.1016\/j.amjmed.2022.05.031"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1542\/pir.2016-0168","article-title":"Congestive heart failure in children","volume":"40","author":"Price","year":"2019","unstructured":"Price JF. Congestive heart failure in children. Pediatr Rev 2019; 40: 60-70.","journal-title":"Pediatr Rev"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1016\/j.jacc.2019.03.478","article-title":"ACC\/AHA versus ESC guidelines on heart failure: JACC guideline comparison","volume":"73","author":"der Meer P","year":"2019","unstructured":"van der Meer P, Gaggin HK and Dec GW. ACC\/AHA versus ESC guidelines on heart failure: JACC guideline comparison. J Am Coll Cardiol 2019; 73: 2756-2768.","journal-title":"J Am Coll Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10741-021-10105-w","article-title":"Biomarkers for the diagnosis and management of heart failure","volume":"27","author":"Castiglione","year":"2022","unstructured":"Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C and Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev 2022; 27: 625-643.","journal-title":"Heart Fail Rev"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR and Yancy CW; ACC\/AHA Joint Committee Members. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 2022; 145: e895-e1032.","DOI":"10.1161\/CIR.0000000000001063"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/0886022X.2021.1874985","article-title":"Ibrutinib-induced acute kidney injury via interstitial nephritis","volume":"43","author":"Markoth","year":"2021","unstructured":"Markoth C, File I, Szasz R, Bidiga L, Balla J and Matyus J. Ibrutinib-induced acute kidney injury via interstitial nephritis. Ren Fail 2021; 43: 335-339.","journal-title":"Ren Fail"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.4155\/fmc-2018-0433","article-title":"Rational modulator design by exploitation of protein-protein complex structures","volume":"11","author":"Wichapong","year":"2019","unstructured":"Wichapong K, Poelman H, Ercig B, Hrdinova J, Liu X, Lutgens E and Nicolaes GA. Rational modulator design by exploitation of protein-protein complex structures. Future Med Chem 2019; 11: 1015-1033.","journal-title":"Future Med Chem"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.hlc.2017.10.020","article-title":"Proton pump inhibitors and cardiovascular events: a systematic review","volume":"27","author":"Shiraev","year":"2018","unstructured":"Shiraev TP and Bullen A. Proton pump inhibitors and cardiovascular events: a systematic review. Heart Lung Circ 2018; 27: 443-450.","journal-title":"Heart Lung Circ"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","article-title":"Reappraising the role of inflammation in heart failure","volume":"17","author":"Adamo","year":"2020","unstructured":"Adamo L, Rocha-Resende C, Prabhu SD and Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol 2020; 17: 269-285.","journal-title":"Nat Rev Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Desbuissons G and Mercadal L. Use of proton pump inhibitors in dialysis patients: a double-edged sword? J Nephrol 2021; 34: 661-672.","DOI":"10.1007\/s40620-020-00808-y"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Yoshihisa A, Takiguchi M, Kanno Y, Sato A, Yokokawa T, Miura S, Abe S, Misaka T, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Nakazato K, Suzuki H, Saitoh SI and Takeishi Y. Associations of acid suppressive therapy with cardiac mortality in heart failure patients. J Am Heart Assoc 2017; 6: e005110.","DOI":"10.1161\/JAHA.116.005110"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3390\/biomedicines11030917","article-title":"Novel oxidative stress biomarkers with risk prognosis values in heart failure","volume":"11","author":"ML","year":"2023","unstructured":"Ng ML, Ang X, Yap KY, Ng JJ, Goh ECH, Khoo BBJ, Richards AM and Drum CL. Novel oxidative stress biomarkers with risk prognosis values in heart failure. Biomedicines 2023; 11: 917.","journal-title":"Biomedicines"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Ali J, Aziz MA, Rashid MMO, Basher MA and Islam MS. Propagation of age-related diseases due to the changes of lipid peroxide and antioxidant levels in elderly people: a narrative review. Health Sci Rep 2022; 5: e650.","DOI":"10.1002\/hsr2.650"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s11010-023-04662-x","article-title":"Lansoprazole attenuates cyclophosphamide-induced cardiopulmonary injury by modulating redox-sensitive pathways and inflammation","volume":"478","author":"Hassanein","year":"2023","unstructured":"Hassanein EHM, Kamel EO, Gad-Elrab WM, Ahmed MA, Mohammedsaleh ZM and Ali FEM. Lansoprazole attenuates cyclophosphamide-induced cardiopulmonary injury by modulating redox-sensitive pathways and inflammation. Mol Cell Biochem 2023; 478: 2319-2335.","journal-title":"Mol Cell Biochem"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/eurheartj\/ehx721","article-title":"Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction","volume":"39","author":"Taqueti","year":"2018","unstructured":"Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT, Hainer J, Bibbo CF, Dorbala S, Blankstein R and Di Carli MF. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J 2018; 39: 840-849.","journal-title":"Eur Heart J"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Cornuault L, Rouault P, Duplaa C, Couffinhal T and Renault MA. Endothelial dysfunction in heart failure with preserved ejection fraction: what are the experimental proofs? Front Physiol 2022; 13: 906272.","DOI":"10.3389\/fphys.2022.906272"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.3390\/ijms24054321","article-title":"Molecular mechanisms and therapeutic implications of endothelial dysfunction in patients with heart failure","volume":"24","author":"Tsigkou","year":"2023","unstructured":"Tsigkou V, Oikonomou E, Anastasiou A, Lampsas S, Zakynthinos GE, Kalogeras K, Katsioupa M, Kapsali M, Kourampi I, Pesiridis T, Marinos G, Vavuranakis MA, Tousoulis D, Vavuranakis M and Siasos G. Molecular mechanisms and therapeutic implications of endothelial dysfunction in patients with heart failure. Int J Mol Sci 2023; 24: 4321.","journal-title":"Int J Mol Sci"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1161\/HYPERTENSIONAHA.116.08408","article-title":"Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction","volume":"69","author":"Onda","year":"2017","unstructured":"Onda K, Tong S, Beard S, Binder N, Muto M, Senadheera SN, Parry L, Dilworth M, Renshall L, Brownfoot F, Hastie R, Tuohey L, Palmer K, Hirano T, Ikawa M, Kaitu’u-Lino T and Hannan NJ. Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction. Hypertension 2017; 69: 457-468.","journal-title":"Hypertension"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"16818","DOI":"10.1021\/acs.jmedchem.2c01635","article-title":"Designing selective drug-like molecular glues for the glucocorticoid receptor\/14-3-3 protein-protein interaction","volume":"65","author":"JS","year":"2022","unstructured":"Pallesen JS, Munier CC, Bosica F, Andrei SA, Edman K, Gunnarsson A, La Sala G, Putra OD, Srdanovic S, Wilson AJ, Wissler L, Ottmann C, Perry MWD and O’Mahony G. Designing selective drug-like molecular glues for the glucocorticoid receptor\/14-3-3 protein-protein interaction. J Med Chem 2022; 65: 16818-16828.","journal-title":"J Med Chem"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/157340211501190129144451","article-title":"Heart failure","volume":"15","author":"Chaudhry","year":"2019","unstructured":"Chaudhry MA. Heart failure. Curr Hypertens Rev 2019; 15: 7.","journal-title":"Curr Hypertens Rev"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/apt.16407","article-title":"Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors","volume":"54","author":"Salvo","year":"2021","unstructured":"Salvo EM, Ferko NC, Cash SB, Gonzalez A and Kahrilas PJ. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther 2021; 54: 129-143.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Corsonello A and Lattanzio F. Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: are they safe? Trends Cardiovasc Med 2019; 29: 353-360.","DOI":"10.1016\/j.tcm.2018.10.008"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.hfc.2019.08.010","article-title":"The cardiorenal syndrome in heart failure","volume":"16","author":"Costanzo","year":"2020","unstructured":"Costanzo MR. The cardiorenal syndrome in heart failure. Heart Fail Clin 2020; 16: 81-97.","journal-title":"Heart Fail Clin"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1089\/omi.2019.0095","article-title":"Discovering innovative drugs targeting both cancer and cardiovascular disease by shared protein-protein interaction network analyses","volume":"23","author":"Tiwari","year":"2019","unstructured":"Tiwari S and Dwivedi UN. Discovering innovative drugs targeting both cancer and cardiovascular disease by shared protein-protein interaction network analyses. OMICS 2019; 23: 417-425.","journal-title":"OMICS"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/2\/ajtr0161357.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:50:34Z","timestamp":1766022634000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/2\/ajtr0161357.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/bzed8420","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}